Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AAR

- PMLiVE

EMA says Lilly’s Lartruvo should not be prescribed

First time EMA has acted on accelerated approval follow-up

- PMLiVE

Rising economic risk casts shadow on Davos meeting

Slowing growth in key economies causing concern

- PMLiVE

UK businesses leaning towards second Brexit vote

Poll comes just ahead of May’s ‘plan B’ Brexit announcement

- PMLiVE

Evenity back on track with FDA panel blessing in osteoporosis

US drugs regulator first rejected the drug due to cardiovascular concerns

- PMLiVE

NICE gives Lilly’s Verzenios chance to compete with rivals

Breast cancer drug also being appraised in novel combination

- PMLiVE

Industry pleads for compromise after Brexit defeat

Prime Minister is more boxed in than ever, but unlikely to be toppled

The UK’s new five-year pricing agreement

Pharma has agreed to capped growth again - in exchange for uptake promises

- PMLiVE

Crunch time as Brexit deal faces ‘meaningful vote’

Rejecting the deal would either result in a no deal or no Brexit, warns May

- PMLiVE

Blackwood returns as new life sciences minister

Replaces James O’Shaughnessy at DHSC

- PMLiVE

Time running out for ‘no-deal’ Brexit medicines laws

Needs parliament clearance before 29 March

Bear and Two Foxes

Givers and Takers

Have we lost the ability to identify the difference between net givers and net takers of energy?

Page & Page and Partners

- PMLiVE

NICE rejects Novartis migraine treatment Aimovig

A draft 'no' to first-in-class treatment, despite discount

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links